Improving access for anti-tumour necrosis factor-α therapy in inflammatory bowel disease

Nicholas A Biehl, Janina Pawlik and Geoffrey M Forbes
Med J Aust 2010; 193 (9): . || doi: 10.5694/j.1326-5377.2010.tb04052.x
Published online: 1 November 2010

To the Editor: Burger and colleagues reported the limitations of pre-August 2010 Pharmaceutical Benefits Scheme (PBS) criteria for subsidised anti-tumour necrosis factor-α (anti-TNF-α) treatment of perianal Crohn’s disease (CD).1 PBS-subsidised infliximab is now available for CD patients with a Crohn’s Disease Activity Index (CDAI) > 300 who have failed to achieve an adequate response to minimum doses of steroids and immunomodulators, and for patients with fistulising CD.2,4

  • Nicholas A Biehl1
  • Janina Pawlik1
  • Geoffrey M Forbes1,2

  • 1 Royal Perth Hospital, Perth, WA.
  • 2 School of Medicine and Pharmacology, University of Western Australia, Perth, WA.



This audit was conducted with support from a Robert Vandongen Vacation Scholarship awarded by Royal Perth Hospital Medical Research Foundation and the University of Western Australia.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.